Moberg Pharma AB (OSTO:MOB) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 05, 2026)


OSTO:MOB Moberg Pharma AB OSTO:MOB
60 GF Score
Price kr9.45
GF Value kr12.45
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Moberg Pharma AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OSTO:MOB vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Margin of Safety % (DCF Earnings Based) falls into.


OSTO:MOB
60GF Score
Moberg Pharma AB OSTO:MOB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moberg Pharma AB (OSTO:MOB) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of kr9.45 is trading 24.1% below its estimated GF Value™ of kr12.45. GuruFocus considers Moberg Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:MOB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr12.45 vs. price of kr9.45 (24.1% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the OSTO:MOB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USA
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score

Get the complete analysis for OSTO:MOB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.45
Price
kr12.45
GF Value